Neuphoria Therapeutics Inc. Increase (Decrease) in Other Noncurrent Liabilities
Neuphoria Therapeutics Inc. (NEUP) reported Increase (Decrease) in Other Noncurrent Liabilities of -$2.89 thousand for the 12-month period ending 2025-06-30, per its 10-K filed 2026-09-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-09-18
- Neuphoria Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-06-30 was -$3.65K, a 334.84% decline year-over-year.
- Neuphoria Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2025-03-31 was $258.00, a 396.15% increase year-over-year.
- Neuphoria Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-12-31 was -$48.00.
- Neuphoria Therapeutics Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2024-09-30 was $551.00, a 66.47% increase year-over-year.
- Neuphoria Therapeutics Inc. increase (decrease) in other noncurrent liabilities for fiscal 2025 was -$2.89K.
- Neuphoria Therapeutics Inc. increase (decrease) in other noncurrent liabilities for fiscal 2024 was -$11.96K, a 248.79% decline from fiscal 2023.
- Neuphoria Therapeutics Inc. increase (decrease) in other noncurrent liabilities for fiscal 2023 was $8.04K.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2025-06-30 | -$3.65K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-18 | -$3.39K derived: sum of 2 quarters · filed 2026-09-18 | -$3.44K derived: sum of 3 quarters · filed 2026-09-18 | -$2.89K 10-K · filed 2026-09-18 |
| 2025-03-31 | $258.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-15 | $210.00 derived: sum of 2 quarters · filed 2026-05-15 | $761.00 10-Q · filed 2026-05-15 | $2.31K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$48.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17 | $503.00 10-Q · filed 2026-02-17 | $2.06K derived: sum of 3 quarters · filed 2026-02-17 | $2.11K derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | $551.00 10-Q · filed 2025-11-14 | $2.10K derived: sum of 2 quarters · filed 2025-11-14 | $2.16K derived: sum of 3 quarters · filed 2025-11-14 | -$11.74K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.55K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | $1.60K derived: sum of 2 quarters · filed 2025-09-29 | -$12.29K derived: sum of 3 quarters · filed 2025-09-29 | -$11.96K 10-K · filed 2025-09-29 |
| 2024-03-31 | $52.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-20 | -$13.85K derived: sum of 2 quarters · filed 2025-05-20 | -$13.52K 10-Q · filed 2025-05-20 | |
| 2023-12-31 | -$13.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$13.57K 10-Q · filed 2025-02-14 | ||
| 2023-09-30 | $331.00 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | $8.04K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |